Short Interest in Mainz Biomed NV (NASDAQ:MYNZ) Rises By 45.5%

Mainz Biomed NV (NASDAQ:MYNZ) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 87,000 shares, anincreaseof45.5% from the July 15th total of 59,800 shares. Currently,2.0% of the company’s shares are sold short. Based on an average trading volume of 148,200 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 148,200 shares, the days-to-cover ratio is presently 0.6 days. Currently,2.0% of the company’s shares are sold short.

Mainz Biomed Price Performance

MYNZ stock opened at $1.72 on Thursday. The business has a fifty day moving average of $1.67 and a two-hundred day moving average of $3.13. The company has a quick ratio of 1.26, a current ratio of 1.32 and a debt-to-equity ratio of 0.14. The stock has a market cap of $7.88 million, a price-to-earnings ratio of -0.03 and a beta of 0.25. Mainz Biomed has a 52-week low of $1.30 and a 52-week high of $18.40.

Institutional Investors Weigh In On Mainz Biomed

A hedge fund recently raised its stake in Mainz Biomed stock. Armistice Capital LLC grew its position in Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 285,000 shares of the company’s stock after buying an additional 88,400 shares during the quarter. Armistice Capital LLC owned 6.23% of Mainz Biomed worth $402,000 as of its most recent filing with the Securities and Exchange Commission.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.